S
Sanjay Kaul
Researcher at Cedars-Sinai Medical Center
Publications - 222
Citations - 25862
Sanjay Kaul is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Randomized controlled trial & Myocardial infarction. The author has an hindex of 67, co-authored 215 publications receiving 22556 citations. Previous affiliations of Sanjay Kaul include University of California, Los Angeles & Baylor University Medical Center.
Papers
More filters
Journal ArticleDOI
Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction
Javed Butler,Gerasimos Filippatos,Tariq Jamal Siddiqi,João Pereira,Martina Brueckmann,Edimar Alcides Bocchi,Michael Böhm,Vijay K. Chopra,P. Giannetti,Tomoko Iwata,James L. Januzzi,Sanjay Kaul,Ileana L. Piña,Piotr Ponikowski,Ursula Rauch-Kröhnert,Michele Senni,Mikhail Sumin,Subodh Verma,Jian Zhang,Stuart J. Pocock,Faiez Zannad,Milton Packer,Stefan D. Anker +22 more
TL;DR: Empagliflozin produced similar benefits on outcomes and health status in women and men with HF and preserved ejection fraction.
Book ChapterDOI
From Vulnerable Plaque to Vulnerable Patient – Part III
Morteza Naghavi,Erling Falk,Harvey S. Hecht,Michael J. Jamieson,Sanjay Kaul,Daniel S. Berman,Zahi A. Fayad,Matthew J. Budoff,John A. Rumberger,Tasneem Z. Naqvi,Leslee J. Shaw,Jay N. Cohn,Ole Faergeman,Raymond D. Bahr,Wolfgang Koenig,Jasenka Demirovic,Dan E. Arking,Victoria L. M. Herrera,Juan J. Badimon,James A. Goldstein,Arturo G. Touchard,Yoram Rudy,K.E. Juhani Airaksinen,Robert S. Schwartz,Ward A. Riley,Robert A. Mendes,Pamela S. Douglas,Prediman K. Shah +27 more
TL;DR: Cardiovascular healthcare professionals and policymakers are urged to adopt the SHAPE proposal and its attendant cost-effectiveness as a new strategy to contain the epidemic of atherosclerotic cardiovascular disease and the rising cost of therapies associated with this epidemic.
Journal ArticleDOI
Making the Case for Selective Use of Statins in the Primary Prevention Setting
C. Michael Minder,Michael J. Blaha,Lori M. Tam,Daniel Muñoz,Erin D. Michos,Sanjay Kaul,Roger S. Blumenthal +6 more
TL;DR: A population-based analysis of the health experience of African Nova Scotians and a comparison of cardiovascular risk profiles among ethnic groups using population health surveys between 1996 and 2007 are presented.
Journal ArticleDOI
On reporting of effect size in randomized clinical trials.
George A. Diamond,Sanjay Kaul +1 more
TL;DR: Results have shown that composite measures of effect size communicate the clinical importance of trial results better than do conventional assessments of risk reduction and statistical significance.
Journal ArticleDOI
Secondary prevention of cardiovascular disease with vorapaxar: a new era of 3-drug antiplatelet therapy?
TL;DR: Physicians should understand the benefit-risk balance of vorapaxar and the drug’s potential role in clinical practice as part of a 3-drug antiplatelet regimen for secondary prevention of myocardial infarction and in peripheral artery disease.